Table 1 Baseline characteristics of total and separate hepatocellular carcinoma groups treated with sorafenib

Age (yrs) (range)

61.04 ± 12.76 (32.00–88.00)

58.75 ± 13.33 (32.0–84.0)

60.36 ± 12.45 (32.0–88.0)

64.50 ± 12.02 (40.0–86.0)

Sex (Male) (%)

127 (81.41)

46 (88.5)

52 (89.66)

29 (63.04)

BMI (kgs/m²) (range)

22.69 ± 3.88(14.10–34.82)

23.05 ± 3.71 (15.24–34.82)

21.92 ± 3.48 (14.10–32.86)

23.26 ± 4.43 (15.56–33.75)

Cirrhosis (+) (%)

120 (76.92)

32 (61.5)

50 (86.21)

38 (82.61)

CPC, score 5 versus 6 (%)

81 (51.92) versus 75 (48.08)

30 (57.7) versus 22 (42.3)

31 (53.45) versus 27 (46.55)

20 (43.48) versus 26 (56.52)

Albumin (g/dL) (range)

3.88 ± 0.50 (2.80–5.10)

4.05 ± 0.42 (3.20–4.80)

3.88 ± 0.51 (2.80–5.10)

3.68 ± 0.51 (2.80–4.70)

Bilirubin (mg/dL) (range)

1.02 ± 0.46 (0.19–2.41)

0.99 ± 0.41 (0.22–1.99)

1.03 ± 0.48 (0.19–2.29)

1.05 ± 0.51 (0.38–2.41)

INR (range)

1.14 ± 0.13 (0.89–1.63)

1.13 ± 0.12 (0.90–1.63)

1.15 ± 0.13 (0.90–1.48)

1.15 ± 0.15 (0.89–1.63)

AST (IU/L) (range)

92.45 ± 105.98 (22.00–805.00)

96.20 ± 102.12 (24.00–580.00)

95.07 ± 136.90 (22.00–805.00)

84.84 ± 53.33 (23.00–237.00)

ALT (IU/L) (range)

66.54 ± 102.12 (9.00–1156.00)

65.73 ± 48.32 (15.00–251.00)

76.86 ± 157.43 (9.00–1156.00)

54.43 ± 39.91 (13.00–202.00)

ALK-P (IU/L) (range)

127.76 ± 93.34 (43.00–680.00)

124.84 ± 81.74 (50.00–421.00)

113.14 ± 93.05 (45.00–680.00)

155.0 ± 104.82 (43.00–526.00)

AFP (ng/mL) (range)

9000.31 ± 17472.65 (0.91–54001.0)

11769.7 ± 19836.59 (1.64–54001.0)

6663.7 ± 14569.6 (0.91–54001.0)

8815.86 ± 17910.81 (1.30–54001.0)

Cr (mg/dL) (range)

0.93 ± 0.35 (0.21–2.76)

0.90 ± 0.30 (0.40–2.10)

0.94 ± 0.32 (0.27–1.76)

0.95 ± 0.43 (0.21–2.76)

WBC (10³/uL) (range)

6.90 ± 3.71 (1.70–22.62)

6.96 ± 3.33 (2.48–17.35)

6.79 ± 3.66 (1.70–19.00)

7.00 ± 4.23 (2.10–22.62)

Hb (gm/dL) (range)

12.48 ± 1.97 (7.90–17.10)

12.63 ± 1.98 (7.90–16.00)

12.64 ± 2.02 (7.90–17.10)

12.11 ± 1.89 (8.10–15.10)

Platelet (10³/uL) (range)

171.49 ± 110.79 (16.00–796.00)

170.69 ± 82.45 (16.00–400.00)

177.19 ± 145.22 (44.00–796.0)

165.2 ± 88.18 (23.00–386.00)

B or C or B + C (+) or NBNC (%)

80 (51.28) or 50 (32.05) or 5 (3.21) or 21 (13.46)

30 (57.7) or 9 (17.3) or 3 (5.8) or 10 (19.2)

33 (56.9) or 18 (31.03) or 1 (1.72) or 6 (10.34)

17 (36.96) or 23 (50.0) or 1 (2.17) or 5(10.87)

Tumor characters

Tumor size (>5 cm) (%)

74 (47.44)

27 (51.9)

25 (43.1)

22 (47.83)

Tumor number (>3) (%)

91 (58.33)

28 (53.8)

32 (55.17)

31 (67.39)

Intra-hepatic vein (+) (%)

61 (39.10)

23 (44.2)

18 (31.03)

20 (43.48)

Extra-hepatic metastases (%)

75 (48.08)

23 (44.2)

31 (53.45)

21 (45.65)

Mixed type (vein and metastases)

20 (12.82)

6 (11.5)

9 (15.52)

5 (10.87)